Edwards Lifesciences Corporation $EW Shares Sold by Sumitomo Mitsui Trust Group Inc.

Posted by Brenda Bartman on Jul 11th, 2026

Sumitomo Mitsui Trust Group Inc. lowered its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 5.6% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,267,383 shares of the medical research company’s stock after selling 74,542 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Edwards Lifesciences were worth $101,492,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after purchasing an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Edwards Lifesciences by 39.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after purchasing an additional 648,870 shares during the last quarter. Central Pacific Bank Trust Division acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $775,000. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $2,984,000. Finally, Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 45,577 shares of company stock worth $3,855,527. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on EW shares. TD Cowen reaffirmed a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. BTIG Research boosted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Barclays restated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $97.09.

Check Out Our Latest Research Report on Edwards Lifesciences

Edwards Lifesciences Trading Up 1.0%

Edwards Lifesciences stock traded up $0.89 during midday trading on Friday, reaching $92.22. 3,381,397 shares of the stock traded hands, compared to its average volume of 4,354,287. The company has a 50-day simple moving average of $86.73 and a two-hundred day simple moving average of $83.87. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The firm has a market cap of $53.10 billion, a PE ratio of 49.05, a price-to-earnings-growth ratio of 2.29 and a beta of 0.86. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.